Related Experiment Videos
Cutaneous leucocytoclastic vasculitis associated with omeprazole
1Department of Internal Medicine B, Bnai Zion Medical Center, and Technion Faculty of Medicine, Israel.
Postgraduate Medical Journal
|January 25, 2002
Summary
Omeprazole, a proton pump inhibitor, is generally well-tolerated. This report details a rare case of cutaneous leucocytoclastic vasculitis (CLV) developing in an elderly patient after omeprazole treatment.
Area of Science:
- Gastroenterology
- Dermatology
- Pharmacology
Background:
- Omeprazole is a widely used proton pump inhibitor (PPI) for acid-related gastrointestinal disorders.
- While generally safe, omeprazole can cause adverse effects, with skin reactions being uncommon.
- Reported cutaneous adverse events include rashes, urticaria, and angio-oedema.
Observation:
- A case study involving an elderly patient who developed a specific skin condition.
- The patient began omeprazole treatment for an unspecified condition.
- Cutaneous leucocytoclastic vasculitis (CLV) emerged four weeks after initiating omeprazole therapy.
Findings:
- Cutaneous leucocytoclastic vasculitis (CLV) is a rare adverse reaction.
- This is the first reported instance of CLV associated with omeprazole use.
- The adverse reaction appeared after a four-week treatment period with omeprazole.
Implications:
- This case highlights a previously undocumented adverse effect of omeprazole.
- Clinicians should consider omeprazole as a potential trigger for CLV in susceptible individuals.
- Further investigation may be warranted to understand the mechanism and incidence of omeprazole-induced CLV.